IP Verse

Antibodies Against Human Cd39 And Use Thereof - EP2654789

The patent EP2654789 was granted to Inserm Institut National DE LA Sant ET DE LA Recherche Mdicale on May 30, 2018. The application was originally filed on Dec 21, 2011 under application number EP11801741A. The patent is currently recorded with a legal status of "Revoked".

EP2654789

INSERM INSTITUT NATIONAL DE LA SANT ET DE LA RECHERCHE MDICALE
Application Number
EP11801741A
Filing Date
Dec 21, 2011
Status
Revoked
Sep 6, 2024
Grant Date
May 30, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BOULT WADE TENNANTFeb 28, 2019BOULT WADE TENNANTADMISSIBLE
D YOUNGFeb 28, 2019HOIBERG PSWITHDRAWN
TIZONA THERAPEUTICSFeb 26, 2019HUTTERADMISSIBLE
ABBVIEFeb 15, 2019MEWBURN ELLISADMISSIBLE

Patent Citations (38) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0125023
DESCRIPTIONEP0173494
DESCRIPTIONEP0239400
DESCRIPTIONEP0519596
DESCRIPTIONEP0592106
DESCRIPTIONUS4179337
DESCRIPTIONUS4301144
DESCRIPTIONUS4496689
DESCRIPTIONUS4640835
DESCRIPTIONUS4670417
DESCRIPTIONUS4791192
DESCRIPTIONUS4816567
DESCRIPTIONUS4861719
DESCRIPTIONUS5202238
DESCRIPTIONUS5204244
DESCRIPTIONUS5225539
DESCRIPTIONUS5278056
DESCRIPTIONUS5530101
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5859205
DESCRIPTIONUS5882877
DESCRIPTIONUS6013516
DESCRIPTIONWO2009095478
DESCRIPTIONWO8702671
DESCRIPTIONWO8705330
DESCRIPTIONWO9109967
DESCRIPTIONWO9419478
DESCRIPTIONWO9514785
DESCRIPTIONWO9602576
DESCRIPTIONWO9622378
DESCRIPTIONWO9710354
DESCRIPTIONWO9845322
INTERNATIONAL-SEARCH-REPORTWO2009095478
OPPOSITIONUS2005158280
OPPOSITIONWO2009095478
OPPOSITIONWO2012085132
OTHERWO2009095478

Non-Patent Literature (NPL) Citations (68) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- Remington's Pharmaceutical Sciences, pages 1035 - 1038,157-
EXAMINATION- J. BASTID ET AL, "Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity", CANCER IMMUNOLOGY RESEARCH, US, (20141117), vol. 3, no. 3, doi:10.1158/2326-6066.CIR-14-0018, ISSN 2326-6066, pages 254 - 265, XP055340441
INTERNATIONAL-SEARCH-REPORT- MEYER ET AL., "Expression of cd39 and CD73 as means of evading anti-tumor immune responses in lung cancer", THE JOURNAL OF IMMUNOLOGY, (201004), vol. 184, XP002668792 [I] 1-13 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- DZHANDZHUGAZYAN KARINE N ET AL, "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas", FEBS LETTERS, (19980703), vol. 430, no. 3, ISSN 0014-5793, pages 227 - 230, XP002668791 [X] 1-4,9-11,13 * the whole document * [I] 5-8,12
INTERNATIONAL-SEARCH-REPORT- JIN DACHUAN ET AL, "CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression", CANCER RESEARCH, (201003), vol. 70, no. 6, ISSN 0008-5472, XP002668793 [I] 1-13 * the whole document *
INTERNATIONAL-SEARCH-REPORT- CLAYTON ALED ET AL, "Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production", JOURNAL OF IMMUNOLOGY, (201107), vol. 187, no. 2, ISSN 0022-1767, pages 676 - 683, XP002668794 [IP] 1-13 * the whole document *
OPPOSITION- Biological deposit receipt for CNCM 1-4171-
OPPOSITION- Biological deposit receipt for CNCM I-3889-
OPPOSITION- CLAYTON et al., "Cancer Exosomes Express CD 39 and CD 73, Which Suppress T Cells through Adenosine Production", Journal of Immunology, (20110000), vol. 187, pages 676 - 683, XP0002668794-
OPPOSITION- GOUTTEFANGEAS et al., "Biochemical analysis and epitope mapping of mAb defining CD 39", Leucocyte Typing V ; White Cell Differentiation Antigens; Proceedings of the 5th International Workshop, (19950000), pages 383 - 385, XP055574782-
OPPOSITION- HAUSLER et al., Geburtsh Frauenheilk, (20080000), vol. 68-
OPPOSITION- HAUSLER et al., Geburtshilfe Frauenheilkunde, (20090000), vol. 69, page 106-
OPPOSITION- MANDAPATHIL et al., "Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer", Clin Cancer Res, (20090000), vol. 15, no. 20, pages 6348 - 6357, XP009126055-
OPPOSITION- MEYER et al., "Expression of CD39 and CD73 as a means of evadinganti­ tumorimmune reponses inlungcancer (100.7)", J Immun, (20100401), vol. 184, no. 1, XP055574707-
OPPOSITION- MEYER et al., "Expression of CD 39 and CD 73 as means of D2 evading antitumor immune responses in lung cancer (100.7)", THE JOURNAL OF IMMUNOLOGY, (20100401), vol. 184, XP002668792-
OPPOSITION- Poster presentation corresponding to abstract Geburtshilfe Frauenheilkunde, (20090000), vol. 69, page 106-
OPPOSITION- RAWSTRON et al., "Chronic Lymphocytic Leukaemia (CLL) and CLL­ Type Monoclonal B-Cell Lymphocytosis (MBL) Show Differential Expression of Molecules Involved in Lymphoid Tissue Homing", Cytometry Part B, (20100000), vol. 78B, pages S42 - S46, XP055574709-
OPPOSITION- SUN et al., "CD39/ENTPD1 Expression by CD4^+Foxp3^+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice", Gastroenterology, (20100625), vol. 139, pages 1030 - 1040, XP027225681-
OPPOSITION- TRAVERSO et al., "365 ANALYSIS OF REGULATORY T CELLS IN PATIENTS AFFECTED BY RENAL CELL CARCINOMA", THE JOURNAL OF UROLOGY, (20100530), vol. 183, no. 4, pages a144 - e145, XP026972635-
OPPOSITION- TUNG-JOU HOU, "COMPARISON OF MULTIPLE COMPARISON METHODS FOR IDENTIFYING DIFFERENTIAL GENE EXPRESSION IN SIMULATED AND REAL PAPILLARY THYROID CANCER MICROARRAY DATA", (20090800), pages FP - 79, XP055574898-
OPPOSITION- SHI et al., "Prevalence of the Mercurial-Sensitive EctoATPase in Human Small Cell Lung Carcinoma: Characterization and Partial Purification", Arch Biochem Biophys, (19940000), vol. 315, no. 1, pages 177 - 184, XP024752537
OPPOSITION- SHI et al., "Prevalence of the Mercurial-Sensitive EctoATPase in Human Small Cell Lung Carcinoma: Characterization and Partial Purification", Archives of Biochemistry and Biophysics, (19940000), vol. 315, pages 177 - 184, XP024752537
OPPOSITION- HAUSLER et al., "Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity", Cancer Immunol Immunother, (20110000), vol. 1011, no. 60, pages 1405 - 1418, XP019954940
OPPOSITION- HAUSLER et al., "Ectonucleotidases CD 39 and CD 73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity", Cancer Immunol. Immunother, (20110000), vol. 60, pages 1405 - 1418, XP019954940
OPPOSITION- HAUSLER et al., "Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity", Cancer Immunol Immunother, (20110603), vol. 60, no. 10, pages 1405 - 1418, XP019954940
OPPOSITION- HÄUSLER et al., "Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity", Cancer Immunol Immunother, (20110603), vol. 60, pages 1405 - 1418, XP019954940
OPPOSITION- WHITESIDE, "Disarming suppressor cells to improve immunotherapy", Cancer Immunol Immunother, vol. 61, (20120000), pages 283 - 288, (20111207), XP035005857
OPPOSITION- ROBSON et al., "The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance", Purinergic Signalling, (20060000), vol. 2, pages 409 - 430, XP019410894
OPPOSITION- DWYER et al., "CD 39 and control of cellular immune responses", Purinergic Signalling, (20070000), vol. 3, pages 171 - 180, XP002485580
OPPOSITION- DWYER et al., "CD39 and control of cellular immune responses", Purinergic Signalling, (20070000), vol. 3, pages 171 - 180, XP019485439
OPPOSITION- BUFFON et al., "NTPDase and 5' ecto-nucleotidase expression profiles and the pattern of extracellular ATP metabolism in the Walker 256 tumor", Biochimica et Biophysica Acta, (20070000), vol. 1770, pages 1259 - 1265, XP022138410
OPPOSITION- DZHANDZHUGAZYAN et al., "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas", FEBS Letters, (19980000), vol. 430, no. 3, pages 227 - 230, XP002668791
OPPOSITION- DZHANDZHUGAZYAN et al., "Ecto-ATP diphosphohydrolase/ CD 39 is overexpressed in differentiated human melanomas", FEBS Letters, (19980000), vol. 430, pages 227 - 230, XP002668791
OPPOSITION- DZHANDZHUGAZYAN et al., "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas", FEBS Letters, (19980703), vol. 430, no. 3, pages 227 - 230, XP002668791
OPPOSITION- DZHANDZHUGAZYAN KARINE N et al., "Ecto-ATP diphosphohydrolase/ CD 39 is overexpressed in differentiated human melanomas", FEBS LETTERS, (19980703), vol. 430, no. 3, ISSN 0014-5793, pages 227 - 230, XP002668791
OPPOSITION- SCHUETZ et al., "Molecular Classification of Renal Tumors by GeneExpression Profiling", J. Molecular Diagnostics, (20050000), vol. 7, no. 2, pages 206 - 218, XP055574882
OPPOSITION- SCHUETZ et al., "Molecular Classification of Renal Tumors by Gene Expression Profiling", Journal of Molecular Diagnostics, (20050500), vol. 7, no. 2, pages 206 - 218, XP055574882
OPPOSITION- SITKOVSKY et al., "Adenosine A2A receptor antagonists: blockade ofadenosinergic effects and T regulatory cells", British Journal of Pharmacology, (20080000), vol. 153, no. S1, pages S457 - S464, XP055248920
OPPOSITION- SITKOVSKY et al., "Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells", British Journal of Pharmacology, (20080000), vol. 153, pages S457 - S464, XP055248920
OPPOSITION- STAGG et al., "Extracellular adenosine triphosphate and adenosine in cancer", Oncogene, (20100000), vol. 29, pages 5346 - 5358, XP055574711
OPPOSITION- BASTID et al., "ENTPD1/CD39 is a promising therapeutic target in oncology", Oncogene, (20130000), vol. 32, no. 14, pages 1743 - 1751, XP002779120
OPPOSITION- B B FREDHOLM, "Adenosine, an endogenous distress signal, modulates tissue damage and repair", Cell Death and Differentiation, (20070000), vol. 14, pages 1315 - 1323, XP055574878
OPPOSITION- HAUSLER et al., "CD 39 wird in vivo und in vitro von Ovarialkarzinomzellen exprimiert und inhibiert die lytische Aktivitat von NK-Zellen", Geburtshilfe Frauenheilkd, (20090000), vol. 69, no. P106, XP055575946
OPPOSITION- HAUSLER et al., "Ovarialkarzinomzellen unterdriicken anti- tumorale durch extrazellulare Generierung von Adenosin via CD39 und CD73", Geburtshilfe Frauenheilkd 2009, vol. 69, no. A042, (20090901), URL: https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0029-1238961, XP055477157
OPPOSITION- HAUSLER et al., "Ovarialkarzinomzellen unterdriicken anti-tumorale Immunantwort durch extrazellulare Generierung von Adenosin via CD 39 und CD 73", Geburtshilfe Frauenheilkd, (20090000), vol. 69, no. A042, XP055477157
OPPOSITION- HAUSLER et al., "Ovarialkarzinomzellen unterdrücken anti-tumorale Immunantworten durch extrazelluläre Generierung von Adenosin via CD39 und CD73", Geburtshilfe Frauenheilkd, (20090000), vol. 69, page A042, XP055477157
OPPOSITION- HAUSLER et al., "Ovarialkarzinomzellen unterdrücken anti-tumorale Immunantworten durch extrazelluläre Generierung von Adenosin via CD39 und CD73", Geburtshilfe Frauenheilkunde, vol. 69, no. A042, (20090900), URL: https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0029-1238961, XP055477157
OPPOSITION- OHTA et al., "A2A adenosine receptor protects tumors from antitumor T cells", PNAS, (20060000), vol. 103, no. 35, pages 13132 - 13137, XP007915452
OPPOSITION- DEAGLIO et al., "Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression", JEM, (20070000), vol. 204, no. 6, pages 1257 - 1265, XP002485581
OPPOSITION- KONDO et al., "Expression of CD73 and its ecto-5'-nucleotidase activity are elevated in papillary thyroid carcinomas", Histopathology, (20060000), vol. 48, pages 612 - 614, XP055574716
OPPOSITION- KISHORE et al., "Expression of NTPDasel and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling", Am J Physiol Renal Physiol, (20050000), vol. 288, pages F1032 - F1043, XP055574807
OPPOSITION- JIN OACHUAN et al., "CD 73 on Tumor Cells Impairs Antitumor T- Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression", CANCER RESEARCH, (20100300), vol. 70, no. 6, ISSN 0008-5472, pages 2245 - 2255, XP002668793
OPPOSITION- ZHANG, "CD73: A Novel Target for Cancer Immunotherapy", Cancer Res, (20100815), vol. 70, no. 16, pages 6407 - 6411, XP055252656
OPPOSITION- MANDAPATHIL et al., "Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer", NIH Public Access Author Manuscript, (20090000), vol. 15, pages 1 - 20, XP055575977
OPPOSITION- BASTID et al., "Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity", Cancer Immunol Res, (20141117), vol. 3, no. 3, pages 254 - 265, XP055340441
OPPOSITION- BASTID et al., "Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity", Cancer Immunol Res, (20150300), vol. 3, no. 3, pages 254 - 265, XP055340441
OPPOSITION- J. BASTID et al., "Inhibition of CD 39 Enzymatic Function at the D5 Surface of Tumor Cells Alleviates Their Immunosuppressive Activity", CANCER IMMUNOLOGY RESEARCH, (20141117), vol. 3, no. 3, ISSN 2326-6066, pages 254 - 265, XP055340441
OPPOSITION- PULTE et al., "CD 39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia", Journal of Translational Medicine, (20070000), vol. 5, no. 23, pages 1 - 10, XP021030169
OPPOSITION- MANDAPATHIL et al., "Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E2 cooperation", NIH Public Access Author Manuscript, (20110900), vol. 11, no. 9, pages 1 - 19, XP055574766
OPPOSITION- FUJAREWICZ et al., "A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping", E ndocrine-Related Cancer, (20070000), vol. 14, pages 809 - 826, XP007915082
OPPOSITION- FUJAREWICZ et al., "A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping", Endo. Related Cancer, (20070000), vol. 14, pages 809 - 826, XP007915082
OPPOSITION- WHITESIDE et al., "The Role of the Adenosinergic Pathway in Immunosuppression Mediated by Human Regulatory T Cells (Treg)", Current Medicinal Chemistry, (20110000), vol. 18, no. 34, pages 5217 - 5223, XP055574907
OPPOSITION- HOSKIN et al., "Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review)", International Journal of Oncology, (20080000), vol. 32, pages 527 - 535, XP055574827
OPPOSITION- CLAYTON ALED et al., "Cancer Exosomes Express CD 39 and CD 73 , Which Suppress T Cells through Adenosine Production", JOURNAL OF IMMUNOLOGY, (20110700), vol. 187, no. 2, ISSN 0022-1767, pages 676 - 683, XP002668794
OPPOSITION- CLAYTON et al., "Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production", J Immunol, (20110000), vol. 187, pages 676 - 683, XP002668794
OPPOSITION- KIINZLI et al., "Upregulation of CD 39/NTPDases and P2 receptors in human pancreatic disease", Am. J. Physiol. Gastrointest. Liver Physiol., (20070000), vol. 292, pages G223 - G230, XP055574755
OPPOSITION- KUNZLI et al., "Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease", Am J Gastrointest Liver Physiol, (20070000), vol. 292, pages G223 - G230, XP055574755
OTHER- HAUSLER et al., "Ovarialkarzinomzellen unterdriücken antitumoraleImmunantworten durch extrazelluläre Generierung von Adenosin via CD39 und CD73", Geburtshilfe Frauenhieilkd, (20090900), vol. 69, page A042, XP055477157

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents